C3 and paroxysmal nocturnal hemoglobinuria: Clinical data confirmed the initial hypothesis, since the C3‐inhibitor pegcetacoplan, the FD‐inhibitor danicopan and the FB‐inhibitor iptacopan all resulted in improved hematological benefit in PNH patients.